AbbVie presents Phase 2 APEX Part B data for zumilokibart in atopic dermatitis at EADV 2026
ABBV•AbbVie said it will present late-breaking Phase 2 data on investigational zumilokibart for moderate-to-severe atopic dermatitis at the 2026 EADV Congress in Vienna, Sept. 30-Oct. 3.
1. Congress presentations
AbbVie flagged new dermatology trial and real-world results for presentation at the 2026 EADV Congress. Late-breaking Phase 2 findings for investigational zumilokibart in moderate-to-severe atopic dermatitis are set to outline efficacy and safety.
2. Additional findings
Late-breaking data for investigational lutikizumab in hidradenitis suppurativa are expected to show activity against key inflammatory drivers. Updated evidence for Skyrizi and Rinvoq across multiple immune-mediated skin diseases is due to cover broader patient groups.
